Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Sociodemographic inequalities in COVID-19 booster vaccination in Peru: a GINI index decomposition analysis

View ORCID ProfileClaudio Intimayta-Escalante, View ORCID ProfileGustavo Tapia-Sequeiros, View ORCID ProfileDaniel Rojas-Bolivar
doi: https://doi.org/10.1101/2023.06.10.23291225
Claudio Intimayta-Escalante
1Facultad de Medicina de San Fernando, Universidad Nacional Mayor de San Marcos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Claudio Intimayta-Escalante
  • For correspondence: claudiontimayta{at}gmail.com
Gustavo Tapia-Sequeiros
2Facultad de Medicina, Universidad Privada de Tacna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gustavo Tapia-Sequeiros
Daniel Rojas-Bolivar
3Asociación para el Desarrollo de la Investigación Estudiantil en Ciencias de la Salud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Rojas-Bolivar
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 vaccine coverage, especially in booster doses, remains a significant issue in Peru. This study aimed to analyze the social determinants that affect vaccine coverage and evaluate sociodemographic inequalities in COVID-19 booster dose vaccination in Peru.

Methods An ecological study was conducted with 196 provinces in Peru. GINI index decomposition analysis was performed to assess the inequality of immunization coverage in these provinces, considering sociodemographic characteristics as sources of inequality (sex, age group, educational level, residence area, and ethnic group). The Oaxaca-Blinder method was utilized to decompose the GINI index into Sk (composition effect), Gk (redistribution effect), Rk (differential effect), share value, and percentage change. Bootstrap method based on percentiles was employed to determine 95% confidence interval values for each GINI index and percentage change in the decomposition analysis.

Results A total of 196 Peruvian provinces were evaluated. Among these, 59.74% had higher education, while 10.37% had no education or only elementary education. White or mestizo individuals accounted for 51.62% of the population. The GINI index decomposition analysis, six months after the start of the third and fourth dose vaccination campaign, revealed higher Sk values for the white or mestizo ethnic group (Sk= 6.46 vs Sk= 3.03), people living in rural (Sk= 6.63 vs Sk= 2.76) or urban areas (Sk= 5.88 vs Sk= 2.76), and those aged between 30 and 64 years (Sk= 6.84 vs Sk= 3.20). The highest Gk values were observed for the Aymara (Gk= 0.92 vs Gk= 0.92), Afro-Peruvian (Gk= 0.61 vs Gk= 0.61), and Quechua (Gk= 0.53 vs Gk= 0.53) ethnic groups, in contrast to the white or mestizo group (Gk= 0.34 vs Gk= 0.34). Furthermore, Rk exhibited high positive values for individuals with university or postgraduate education (Rk= 0.59 vs Rk= 0.44) and those living in urban areas (Rk= 0.34 vs Rk= 0.28). Conversely, individuals living in rural areas (Rk= -0.34 vs Rk= -0.28), those with elementary education (Rk= -0.46 vs. Rk= -0.36), and those with no education or only preschool education (Rk= -0.41 vs. Rk= -0.32) displayed high negative Rk values.

Conclussion Sociodemographic inequalities exist in the coverage of third and fourth booster doses against COVID-19 in Peruvian provinces, particularly concerning geographic location, ethnicity, and educational level.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was self-funded

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was developed with open data at the level of the 196 provinces in Peru, which does not allow the identification of any individual. Therefore, there was no intervention on humans. So, ethical board approval was not mandatory

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The data used in the study are available in the National Institute of Statistics and Informatics platform (https://censo2017.inei.gob.pe/resultados-definitivos-de-los-censos-nacionales-2017/), Open Data National Platform in Peru (https://www.datosabiertos.gob.pe/dataset/casos-positivos-por-covid-19-ministerio-de-salud-minsa), and website of the Ministry of Health (https://www.minsa.gob.pe/reunis/data/vacunas-covid19.asp).

https://censo2017.inei.gob.pe/resultados-definitivos-de-los-censos-nacionales-2017/

https://www.datosabiertos.gob.pe/dataset/casos-positivos-por-covid-19-ministerio-de-salud-minsa

https://www.minsa.gob.pe/reunis/data/vacunas-covid19.asp

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 12, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Sociodemographic inequalities in COVID-19 booster vaccination in Peru: a GINI index decomposition analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Sociodemographic inequalities in COVID-19 booster vaccination in Peru: a GINI index decomposition analysis
Claudio Intimayta-Escalante, Gustavo Tapia-Sequeiros, Daniel Rojas-Bolivar
medRxiv 2023.06.10.23291225; doi: https://doi.org/10.1101/2023.06.10.23291225
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Sociodemographic inequalities in COVID-19 booster vaccination in Peru: a GINI index decomposition analysis
Claudio Intimayta-Escalante, Gustavo Tapia-Sequeiros, Daniel Rojas-Bolivar
medRxiv 2023.06.10.23291225; doi: https://doi.org/10.1101/2023.06.10.23291225

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)